BIO-TECHNE DECLARES DIVIDEND
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) has announced a quarterly dividend of $0.08 per share for the quarter ended June 30, 2025. The dividend will be payable on August 29, 2025, to shareholders of record as of August 18, 2025.
The company, a global life sciences leader providing innovative tools and bioactive reagents for research and clinical diagnostics, reported net sales of $1.2 billion in fiscal 2025 and employs approximately 3,100 people worldwide. Bio-Techne's products support scientific research into biological processes, disease progression, drug discovery, and clinical diagnostics.
Positive
- Generated significant revenue of $1.2 billion in fiscal 2025
- Maintains consistent shareholder returns through quarterly dividend program
- Strong market presence with thousands of products in portfolio
Negative
- Relatively small dividend amount of $0.08 per share
- Faces increasing competition in biotechnology research products market
- Subject to currency exchange rate fluctuation risks
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
Contact: | David Clair, Vice President, Investor Relations & Corporate Development |
612-656-4416 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-302522476.html
SOURCE Bio-Techne Corporation
FAQ
What is Bio-Techne's (NASDAQ: TECH) latest dividend amount and payment date?
How much revenue did Bio-Techne generate in fiscal 2025?
How many employees does Bio-Techne have globally?
What are the main business areas of Bio-Techne (NASDAQ: TECH)?
When is the record date for Bio-Techne's latest dividend?
